AbbVie (ABBV) Equity Average (2013 - 2026)

AbbVie has disclosed Equity Average across 14 years of filings, most recently posting -$5.0 billion for Q1 2026.

• In Q1 2026, Equity Average fell 305.68% year-over-year to -$5.0 billion; the TTM figure through Mar 2026 stood at -$5.0 billion (down 305.68% YoY), while the FY2025 annual figure was $47.0 million, down 99.32% from the prior year.
• Equity Average fell to -$5.0 billion in Q1 2026, from -$3.0 billion in the prior quarter.
• Over the last five years, Equity Average for ABBV reached as high as $16.7 billion in Q4 2022 and fell as low as -$5.0 billion in Q1 2026.
• The 5-year median for Equity Average is $9.2 billion (2024), against an average of $8.1 billion.
• Annual changes were most pronounced in 2022 — Equity Average gained 18.34% — and 2026, when it tumbled 305.68%.
• A 5-year view of Equity Average shows it stood at $16.7 billion in 2022, then slumped by 32.38% to $11.3 billion in 2023, then plunged by 58.12% to $4.7 billion in 2024, then sank by 162.66% to -$3.0 billion in 2025, then tumbled by 67.9% to -$5.0 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered -$5.0 billion, -$3.0 billion, and -$1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.